Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma

Experience with 27 patients

Pier Luigi Zinzani, Umberto Vitolo, Simonetta Viviani, Paolo Corradini, Giovanna Motta, Monica Tani, Nicola Cascavilla, Stefan Hohaus, Francesco Merli, Lisa Argnani, Alessandro Broccoli

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background The optimal treatment of patients with heavily pretreated Hodgkin's lymphoma is controversial. Brentuximab vedotin is an active single agent in this context. Also, bendamustine can be regarded as a safe and effective alternative for patients with relapse after autologous transplantation and as an interesting cytoreductive strategy before allogeneic transplantation. Patients and Methods An observational, multicenter, retrospective study is reported of single-agent bendamustine in 27 heavily pretreated patients with relapsed or refractory Hodgkin's lymphoma, who had all received brentuximab vedotin as their last treatment and who showed disease progression, refractory disease, or early relapse. The primary study endpoint was the objective response rate, and the secondary endpoint was the safety of the bendamustine regimen. Results The overall response rate was 55.5%, with 10 of 27 patients (37.0%) obtaining a complete response. In comparison, the overall response rate previously observed with brentuximab vedotin in the same subset of patients was much lower (18.5%). Among the 10 patients with a complete response after bendamustine, only 1 had had a complete response to brentuximab, with 2 having a partial response and 7 stable or progressive disease. With a median duration of response of 8 months, all these patients had maintained a continuous response at the last follow-up examination. The treatment was well tolerated, with rather infrequent adverse events and transient and manageable toxicities. Conclusion Albeit with the limits of an observational retrospective study, these data indicate that bendamustine shows its efficacy in patients already treated with brentuximab vedotin, regardless of their previously obtained response and without any significant toxicity.

Original languageEnglish
Pages (from-to)404-408
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Volume15
Issue number7
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Hodgkin Disease
Safety
Retrospective Studies
Bendamustine Hydrochloride
cAC10-vcMMAE
Recurrence
Autologous Transplantation
Homologous Transplantation
Multicenter Studies
Observational Studies
Disease Progression
Therapeutics

Keywords

  • Bendamustine
  • Brentuximab vedotin
  • Hodgkin's lymphoma
  • Refractory
  • Relapsed

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma : Experience with 27 patients. / Zinzani, Pier Luigi; Vitolo, Umberto; Viviani, Simonetta; Corradini, Paolo; Motta, Giovanna; Tani, Monica; Cascavilla, Nicola; Hohaus, Stefan; Merli, Francesco; Argnani, Lisa; Broccoli, Alessandro.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, No. 7, 01.07.2015, p. 404-408.

Research output: Contribution to journalArticle

@article{585809069dad4342b936898f95a04cdc,
title = "Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma: Experience with 27 patients",
abstract = "Background The optimal treatment of patients with heavily pretreated Hodgkin's lymphoma is controversial. Brentuximab vedotin is an active single agent in this context. Also, bendamustine can be regarded as a safe and effective alternative for patients with relapse after autologous transplantation and as an interesting cytoreductive strategy before allogeneic transplantation. Patients and Methods An observational, multicenter, retrospective study is reported of single-agent bendamustine in 27 heavily pretreated patients with relapsed or refractory Hodgkin's lymphoma, who had all received brentuximab vedotin as their last treatment and who showed disease progression, refractory disease, or early relapse. The primary study endpoint was the objective response rate, and the secondary endpoint was the safety of the bendamustine regimen. Results The overall response rate was 55.5{\%}, with 10 of 27 patients (37.0{\%}) obtaining a complete response. In comparison, the overall response rate previously observed with brentuximab vedotin in the same subset of patients was much lower (18.5{\%}). Among the 10 patients with a complete response after bendamustine, only 1 had had a complete response to brentuximab, with 2 having a partial response and 7 stable or progressive disease. With a median duration of response of 8 months, all these patients had maintained a continuous response at the last follow-up examination. The treatment was well tolerated, with rather infrequent adverse events and transient and manageable toxicities. Conclusion Albeit with the limits of an observational retrospective study, these data indicate that bendamustine shows its efficacy in patients already treated with brentuximab vedotin, regardless of their previously obtained response and without any significant toxicity.",
keywords = "Bendamustine, Brentuximab vedotin, Hodgkin's lymphoma, Refractory, Relapsed",
author = "Zinzani, {Pier Luigi} and Umberto Vitolo and Simonetta Viviani and Paolo Corradini and Giovanna Motta and Monica Tani and Nicola Cascavilla and Stefan Hohaus and Francesco Merli and Lisa Argnani and Alessandro Broccoli",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.clml.2015.02.023",
language = "English",
volume = "15",
pages = "404--408",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "7",

}

TY - JOUR

T1 - Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma

T2 - Experience with 27 patients

AU - Zinzani, Pier Luigi

AU - Vitolo, Umberto

AU - Viviani, Simonetta

AU - Corradini, Paolo

AU - Motta, Giovanna

AU - Tani, Monica

AU - Cascavilla, Nicola

AU - Hohaus, Stefan

AU - Merli, Francesco

AU - Argnani, Lisa

AU - Broccoli, Alessandro

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background The optimal treatment of patients with heavily pretreated Hodgkin's lymphoma is controversial. Brentuximab vedotin is an active single agent in this context. Also, bendamustine can be regarded as a safe and effective alternative for patients with relapse after autologous transplantation and as an interesting cytoreductive strategy before allogeneic transplantation. Patients and Methods An observational, multicenter, retrospective study is reported of single-agent bendamustine in 27 heavily pretreated patients with relapsed or refractory Hodgkin's lymphoma, who had all received brentuximab vedotin as their last treatment and who showed disease progression, refractory disease, or early relapse. The primary study endpoint was the objective response rate, and the secondary endpoint was the safety of the bendamustine regimen. Results The overall response rate was 55.5%, with 10 of 27 patients (37.0%) obtaining a complete response. In comparison, the overall response rate previously observed with brentuximab vedotin in the same subset of patients was much lower (18.5%). Among the 10 patients with a complete response after bendamustine, only 1 had had a complete response to brentuximab, with 2 having a partial response and 7 stable or progressive disease. With a median duration of response of 8 months, all these patients had maintained a continuous response at the last follow-up examination. The treatment was well tolerated, with rather infrequent adverse events and transient and manageable toxicities. Conclusion Albeit with the limits of an observational retrospective study, these data indicate that bendamustine shows its efficacy in patients already treated with brentuximab vedotin, regardless of their previously obtained response and without any significant toxicity.

AB - Background The optimal treatment of patients with heavily pretreated Hodgkin's lymphoma is controversial. Brentuximab vedotin is an active single agent in this context. Also, bendamustine can be regarded as a safe and effective alternative for patients with relapse after autologous transplantation and as an interesting cytoreductive strategy before allogeneic transplantation. Patients and Methods An observational, multicenter, retrospective study is reported of single-agent bendamustine in 27 heavily pretreated patients with relapsed or refractory Hodgkin's lymphoma, who had all received brentuximab vedotin as their last treatment and who showed disease progression, refractory disease, or early relapse. The primary study endpoint was the objective response rate, and the secondary endpoint was the safety of the bendamustine regimen. Results The overall response rate was 55.5%, with 10 of 27 patients (37.0%) obtaining a complete response. In comparison, the overall response rate previously observed with brentuximab vedotin in the same subset of patients was much lower (18.5%). Among the 10 patients with a complete response after bendamustine, only 1 had had a complete response to brentuximab, with 2 having a partial response and 7 stable or progressive disease. With a median duration of response of 8 months, all these patients had maintained a continuous response at the last follow-up examination. The treatment was well tolerated, with rather infrequent adverse events and transient and manageable toxicities. Conclusion Albeit with the limits of an observational retrospective study, these data indicate that bendamustine shows its efficacy in patients already treated with brentuximab vedotin, regardless of their previously obtained response and without any significant toxicity.

KW - Bendamustine

KW - Brentuximab vedotin

KW - Hodgkin's lymphoma

KW - Refractory

KW - Relapsed

UR - http://www.scopus.com/inward/record.url?scp=84937516543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937516543&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2015.02.023

DO - 10.1016/j.clml.2015.02.023

M3 - Article

VL - 15

SP - 404

EP - 408

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 7

ER -